Related Experiment Videos
Early versus delayed hormonal therapy in advanced prostate cancer
1Department of Urology, University Hospital, Lille, France.
European Urology
|January 1, 1996
Summary
Early androgen deprivation therapy for advanced prostate cancer (PCa) delays disease progression and may improve quality of life. While survival benefits require further study, early treatment is recommended for most patients.
Area of Science:
- Oncology
- Urology
Background:
- Androgen deprivation therapy (ADT) is established for advanced prostate cancer (PCa).
- Optimal timing for initiating ADT remains a key clinical question.
- Debate exists on whether to start ADT at diagnosis or delay until symptoms appear.
Purpose of the Study:
- To review current perspectives on the optimal timing of ADT for advanced PCa.
- To evaluate the implications of early versus delayed ADT initiation.
- To synthesize evidence regarding treatment scheduling in advanced prostate cancer management.
Main Methods:
- Literature review of current thinking on ADT timing.
- Analysis of studies comparing early versus delayed hormonal therapy.
- Synthesis of clinical evidence and expert opinion.
Main Results:
- Early ADT significantly delays the onset of disease progression in advanced PCa.
- Delayed ADT initiation was a common practice but is being reassessed.
- Early treatment may correlate with improved quality of life.
Conclusions:
- Early ADT is increasingly recommended for advanced PCa patients.
- While survival benefits are not definitively proven, early intervention shows promise.
- Except for specific patient preferences (e.g., maintaining sexual activity), early ADT should be considered for all advanced PCa cases.